Tocilizumab Treatment for Microvascular Inflammation and Chronic Active Antibody-mediated Rejection in Kidney Transplantation
This study suggests that monthly treatment with the anti-IL-6 receptor monoclonal antibody, tocilizumab, may stabilize allograft function among kidney transplant patients with chronic active AMR and that further studies to confirm its efficacy should be conducted.
Authors
- Reiad Najjar (ORCID: https://orcid.org/0000-0002-6298-0142)
- Edmund Huang (ORCID: https://orcid.org/0000-0001-5356-9290)
- Ashley Vo (ORCID: https://orcid.org/0000-0003-4492-5331)
- Sindhu Chandran (ORCID: https://orcid.org/0000-0003-4547-3381)
- Stanley C. Jordan (ORCID: https://orcid.org/0000-0002-0456-8635)
- Michie Adjei (ORCID: https://orcid.org/0000-0001-8270-2345)
- Jun Shoji (ORCID: https://orcid.org/0000-0002-2505-6372)
- Ai Peng (ORCID: https://orcid.org/0000-0002-3371-0370)
Institutions
- Cedars-Sinai Medical Center (US)
Publication Details
- Journal
- Transplantation Direct
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1097/txd.0000000000001867
- Citations
- 1
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.99